Lin Peng, Zhou Boliang, Yao Haiying
Peng Lin, Department of Hematology, Baoding No.1 Central Hospital, Baoding, Hebei, China.
Boliang Zhou, Department of General Surgery, Baoding No.1 Central Hospital, Baoding, Hebei, China.
Pak J Med Sci. 2021 Jan-Feb;37(1):21-27. doi: 10.12669/pjms.37.1.2563.
In China, for economic reasons, induction regimes for acute myeloid leukemia (AML) often involve domestically produced idarubicin (IDA) rather than imported IDA. Our objective was to compare the effectiveness of induction regimens in combination with cytarabine; involving imported or domestic IDA, or daunorubicin (DNR).
The study was conducted from 1 July 2012 to 30 November 2015 at Baoding No.1 Central Hospital. This was a retrospective cohort study of patients with newly diagnosed AML admitted to Baoding First Central Hospital, China. Patients were divided into three groups according to their treatment regimen: the IA-imported group, the IA-domestic group, and the DNR group. Clinical data, complete remission (CR), partial remission (PR), non-remission (NR) rates, and side effects were compared.
Total 282 patients were enrolled, including 123 patients in the IA-imported group, 98 in the IA-domestic group and 61 in the DNR group. The IA-domestic and IA-imported groups' remission rates were similar (P=0.123) but significantly different from the DNR group (both P<0.05). Side effects were similar in all three groups and no severe side effects were reported.
Cytarabine induction regimens showed similar remission rates in combination with IDA produced in China compared to imported IDA and were more effective than DNR.
在中国，出于经济原因，急性髓系白血病（AML）的诱导方案常使用国产伊达比星（IDA）而非进口伊达比星。我们的目的是比较联合阿糖胞苷的诱导方案的有效性；这些方案涉及进口或国产伊达比星，或柔红霉素（DNR）。
该研究于2012年7月1日至2015年11月30日在保定市第一中心医院进行。这是一项对中国保定市第一中心医院收治的新诊断AML患者的回顾性队列研究。根据治疗方案将患者分为三组：IA进口组、IA国产组和DNR组。比较临床数据、完全缓解（CR）、部分缓解（PR）、未缓解（NR）率及副作用。
共纳入282例患者，其中IA进口组123例，IA国产组98例，DNR组61例。IA国产组和IA进口组的缓解率相似（P = 0.123），但与DNR组有显著差异（均P < 0.05）。三组副作用相似，未报告严重副作用。
与进口伊达比星相比，阿糖胞苷诱导方案联合中国产伊达比星的缓解率相似，且比柔红霉素更有效。
